Alexion Pharmaceuticals is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion markets Soliris(TM)(eculizumab) in the United States for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with severe disease states, including hematologic diseases, cancer and autoimmune disorders, and in May 2007, received a corporate leadership award from the National Organization of Rare Disorders (NORD) for the development of Soliris. Alexion applied for marketing authorization with the European Medicines Evaluation Agency (EMEA) for Soliris in September 2006, and in April 2007 the Committee for Human Medicinal Products (CHMP) of the EMEA adopted a positive opinion recommending marketing authorization for Soliris for the treatment of PNH. In June 2007 the EC approved Soliris for the treatment ...

Contact Information

352 Knotter Drive
Cheshire, CT 06410

tel: 203-272-2596
fax: 203-271-8198


Investor Relations



Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $2.5B

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.